MEREO BIOPHARMA (MREO)
(Delayed Data from NSDQ)
$2.95 USD
+0.02 (0.68%)
Updated May 24, 2024 04:00 PM ET
After-Market: $2.96 +0.01 (0.34%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for MEREO BIOPHARMA falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 57 | 70 | 130 | 30 | 21 |
Receivables | 0 | 2 | 3 | 2 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 5 | 4 | 6 | 16 |
Total Current Assets | 64 | 77 | 137 | 38 | 39 |
Net Property & Equipment | 0 | 2 | 3 | 2 | 15 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 1 | 30 | 34 | 41 | 57 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 67 | 109 | 174 | 81 | 110 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 4 | 3 | 4 | 8 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 19 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 5 | 6 | 5 | 5 | 7 |
Income Taxes Payable | 0 | 0 | 2 | 0 | 0 |
Other Current Liabilities | 1 | 21 | 6 | 1 | 1 |
Total Current Liabilities | 9 | 31 | 17 | 11 | 38 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 4 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 20 | 21 | 7 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 0 | 13 | 67 | 2 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 16 | 32 | 53 | 100 | 59 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 3 | 2 | 2 | 1 | 0 |
Capital Surplus | 486 | 479 | 519 | 373 | 231 |
Retained Earnings | -420 | -410 | -408 | -398 | -187 |
Other Equity | -17 | 5 | 8 | 5 | 7 |
Treasury Stock | 1 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 51 | 77 | 121 | -19 | 51 |
Total Liabilities & Shareholder's Equity | 67 | 109 | 174 | 81 | 110 |
Total Common Equity | 51 | 77 | 121 | -19 | 51 |
Shares Outstanding | 140.20 | 124.90 | 116.90 | 67.70 | 24.90 |
Book Value Per Share | 0.36 | 0.61 | 1.04 | -0.28 | 2.06 |
Fiscal Year End for MEREO BIOPHARMA falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 49 | 57 | -99,999 | -99,946 | 0 |
Receivables | 0 | 0 | NA | 11 | 0 |
Notes Receivable | 0 | 0 | NA | NA | 0 |
Inventories | 0 | 0 | NA | NA | 0 |
Other Current Assets | 5 | 6 | NA | 4 | 0 |
Total Current Assets | 54 | 64 | NA | 68 | 0 |
Net Property & Equipment | 0 | 0 | NA | 2 | 0 |
Investments & Advances | 0 | 0 | NA | NA | 0 |
Other Non-Current Assets | 0 | 0 | NA | NA | 0 |
Deferred Charges | 0 | 0 | NA | NA | 0 |
Intangibles | 1 | 1 | NA | 31 | 0 |
Deposits & Other Assets | 0 | 0 | NA | NA | 0 |
Total Assets | 56 | 67 | NA | 101 | 0 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | 5 | 0 | NA | NA | 0 |
Accounts Payable | 2 | 2 | NA | 2 | 0 |
Current Portion Long-Term Debt | 0 | 0 | NA | 5 | 0 |
Current Portion Capital Leases | 0 | 0 | NA | NA | 0 |
Accrued Expenses | 3 | 5 | NA | 6 | 0 |
Income Taxes Payable | 0 | 0 | NA | NA | 0 |
Other Current Liabilities | 1 | 1 | NA | 8 | 0 |
Total Current Liabilities | 11 | 9 | NA | 22 | 0 |
Mortgages | 0 | 0 | NA | NA | 0 |
Deferred Taxes/Income | 0 | 0 | NA | NA | 0 |
Convertible Debt | 0 | 4 | NA | 5 | 0 |
Long-Term Debt | 0 | 0 | NA | NA | 0 |
Non-Current Capital Leases | 0 | 0 | NA | NA | 0 |
Other Non-Current Liabilities | 1 | NA | 1 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | NA | NA | 0 |
Total Liabilities | 13 | 16 | NA | 29 | 0 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | NA | NA | 0 |
Common Stock (Par) | 3 | 3 | NA | 2 | 0 |
Capital Surplus | 487 | 486 | NA | 491 | 0 |
Retained Earnings | -429 | -420 | NA | -428 | 0 |
Other Equity | -18 | -17 | NA | 7 | 0 |
Treasury Stock | 0 | 1 | NA | NA | 0 |
Total Shareholder's Equity | 43 | 51 | NA | 72 | 0 |
Total Liabilities & Shareholder's Equity | 56 | 67 | NA | 101 | 0 |
Total Common Equity | 43 | 51 | 0 | 100,071 | 0 |
Shares Outstanding | 140.20 | 140.20 | 124.90 | 124.90 | 124.90 |
Book Value Per Share | 0.31 | 0.36 | 0.00 | 801.21 | 0.00 |